CHIKV VLP, adjuvanted
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus
Conditions
Chikungunya Virus
Trial Timeline
Oct 11, 2021 → May 5, 2022
NCT ID
NCT05065983About CHIKV VLP, adjuvanted
CHIKV VLP, adjuvanted is a phase 2 stage product being developed by Bavarian Nordic for Chikungunya Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT05065983. Target conditions include Chikungunya Virus.
What happened to similar drugs?
0 of 11 similar drugs in Chikungunya Virus were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05065983 | Phase 2 | Completed |
Competing Products
20 competing products in Chikungunya Virus